ACS AND AMI 2023 CONTEMPORARY TOPICS

Saturday, February 25, 2023

4:53 PM – 5:40 PM ET

Moderator(s)

George Dangas, MD, MACC, MSCAI

PROFESSOR OF CARDIOLOGY
The Mount Sinai Hospital
New York, New York, United States

Disclosure information not submitted.
C. Michael Gibson, MD

Professor of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States

Disclosure(s): Absolutys: Shareholder (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); AstraZeneca Pharmaceuticals: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing); Bioclinica: Consultant (Ongoing); Boston Clinical Research Institute: Consultant (Ongoing), Owner/Co-Owner Founder/Co-Founder (Ongoing); Boston Scientific: Consultant (Ongoing); Bristol Meyers Squibb: Consultant (Ongoing); Caladrius Bioscience: Consultant (Ongoing); Cardiovascular Research Foundation: Consultant (Ongoing); CeleCor Therapeutics: Consultant (Ongoing); CSL-Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); Cytokinetics: Consultant (Ongoing); Daiichi Sankyo, Inc.: Consultant (Ongoing); Duke Clinical Research Institute: Consultant (Ongoing); Dyad Medical: Shareholder (Ongoing); EXCITE International: Advisor (Ongoing); Fortress Biotech: Consultant (Ongoing), Shareholder (Ongoing); Gilead: Consultant (Ongoing); Inari: Consultant (Ongoing); Janssen Research & Development LLC: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Johnson & Johnson: Consultant (Ongoing), Grant/Research Support (Ongoing); MashUP MD: Consultant (Ongoing); MD Magazine: Consultant (Ongoing); MedImmune: Consultant (Ongoing); Medtelligence: Consultant (Ongoing); Merck Pharmaceuticals: Consultant (Ongoing); Microdrop: Consultant (Ongoing); MicroPort Medical: Consultant (Ongoing); Miracor: Consultant (Ongoing); MJH Life Sciences: Consultant (Ongoing); nference: Shareholder (Ongoing); Novartis Pharmaceuticals: Consultant (Ongoing); NovoNordisk: Consultant (Ongoing); Paratek: Consultant (Ongoing); PERT Consortium: Consultant (Ongoing); Pfizer: Consultant (Ongoing); PhaseBio: Consultant (Ongoing); plx pharma: Consultant (Ongoing); Revance Therapeutics: Consultant (Ongoing); Solstic Health/New Amsterdam Pharma: Consultant (Ongoing); Somahlution/Marizyme: Consultant (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing); Vecutra: Consultant (Ongoing); WebMD: Consultant (Ongoing); Woman As One: Consultant (Ongoing)
Sanjit S. Jolly, MD, MSc

Professor
Population Health Research Institute, Mc Master University, Hamilton Health Sciences
Hamilton, Ontario, Canada

Disclosure(s): Boston Scientific: Grant/Research Support (Ongoing); Penumbra, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing)
Michele D. Voeltz, MD, FACC, FSCAI

Attending Physician
Northside Cardiovascular Institute
Buford, Georgia, United States

Disclosure(s): No relevant disclosure to display

Disclosure(s):

C. Michael Gibson, MD: Absolutys: Shareholder (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); AstraZeneca Pharmaceuticals: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing); Bioclinica: Consultant (Ongoing); Boston Clinical Research Institute: Consultant (Ongoing), Owner/Co-Owner Founder/Co-Founder (Ongoing); Boston Scientific: Consultant (Ongoing); Bristol Meyers Squibb: Consultant (Ongoing); Caladrius Bioscience: Consultant (Ongoing); Cardiovascular Research Foundation: Consultant (Ongoing); CeleCor Therapeutics: Consultant (Ongoing); CSL-Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); Cytokinetics: Consultant (Ongoing); Daiichi Sankyo, Inc.: Consultant (Ongoing); Duke Clinical Research Institute: Consultant (Ongoing); Dyad Medical: Shareholder (Ongoing); EXCITE International: Advisor (Ongoing); Fortress Biotech: Consultant (Ongoing), Shareholder (Ongoing); Gilead: Consultant (Ongoing); Inari: Consultant (Ongoing); Janssen Research & Development LLC: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Johnson & Johnson: Consultant (Ongoing), Grant/Research Support (Ongoing); MashUP MD: Consultant (Ongoing); MD Magazine: Consultant (Ongoing); MedImmune: Consultant (Ongoing); Medtelligence: Consultant (Ongoing); Merck Pharmaceuticals: Consultant (Ongoing); Microdrop: Consultant (Ongoing); MicroPort Medical: Consultant (Ongoing); Miracor: Consultant (Ongoing); MJH Life Sciences: Consultant (Ongoing); nference: Shareholder (Ongoing); Novartis Pharmaceuticals: Consultant (Ongoing); NovoNordisk: Consultant (Ongoing); Paratek: Consultant (Ongoing); PERT Consortium: Consultant (Ongoing); Pfizer: Consultant (Ongoing); PhaseBio: Consultant (Ongoing); plx pharma: Consultant (Ongoing); Revance Therapeutics: Consultant (Ongoing); Solstic Health/New Amsterdam Pharma: Consultant (Ongoing); Somahlution/Marizyme: Consultant (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing); Vecutra: Consultant (Ongoing); WebMD: Consultant (Ongoing); Woman As One: Consultant (Ongoing)

Sanjit S. Jolly, MD, MSc: Boston Scientific: Grant/Research Support (Ongoing); Penumbra, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing)

Michele D. Voeltz, MD, FACC, FSCAI: No relevant disclosure to display